Pilot Clinical Trial of CPC/rhBMP-2 Microffolds as Bone Substitute for Bone Regeneration

NCT02609074 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2015-11-20

No results posted yet for this study

Summary

Objective: The investigators initiated a pilot clinical study to test safety and preliminary efficacy in humans (bone tissue repairing capacity) and to evaluate standard clinical and rehabilitation protocols.

Summary Background Data: Bone tissue engineering scaffolds loading growth factors have been considered as the most perspective among all bone substitutes, yet little progress of its clinical translation has been made. The concept of "micro-scaffolds" was proposed in this study to provide a trajectory to its clinical translation.

Methods: Pre-cured CPC/rhBMP-2 micro-scaffolds have been successfully developed and further applied as an easy-to-operate filler for bone regeneration in a pilot clinical study. Patients of tibial plateau fractures, proximal humeral fractures, or calcaneal fractures at a similar level of severity were randomly divided into two groups and treated by CPC/rhBMP-2 microffolds or traditional CPC paste (control group).

Conditions

  • Bone Fracture

Interventions

PROCEDURE

Minimally invasive internal fixation surgeries

DEVICE

CPC/rhBMP-2 micro-scaffolds

DEVICE

CPC paste

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator OTHER
  • Shanghai 6th People's Hospital

    collaborator OTHER
  • Shanghai Zhongshan Hospital

    collaborator OTHER
  • East China University of Science and Technology

    lead OTHER

Principal Investigators

  • Changsheng Liu, Ph.D. · Engineering Research Center for Biomaterials of Ministry of Education, East China University of Science and Technology

  • Yuan Yuan, Ph.D. · Engineering Research Center for Biomaterials of Ministry of Education, East China University of Science and Technology

  • Jinwu Wang, Ph.D. · Ninth People's Hospital of Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-06-30
Completion
2015-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609074 on ClinicalTrials.gov